Several risk factors have been associated with the development of cholangiocarcinoma. Chronic infection with liver flukes, as mentioned earlier, is a major risk factor in endemic regions. Other risk factors include primary sclerosing cholangitis (an inflammatory condition of the bile ducts), hepatolithiasis (presence of stones in the bile ducts), chronic hepatitis B and C infections, alcohol consumption, obesity, smoking, and exposure to certain chemicals and toxins. The global Cholangiocarcinoma Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8 % during the forecast period (2021-2028).
Diagnosing cholangiocarcinoma can be challenging due to its nonspecific symptoms and the absence of reliable screening tests. Imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are commonly used to detect and evaluate the extent of the disease. Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC) are invasive procedures that allow direct visualization of the bile ducts and tissue sampling for pathological examination. Tumor markers such as carbohydrate antigen 19-9 (CA 19-9) are also measured to aid in diagnosis and monitor treatment response.
Competitive Landscape:
Key players involved in the growth of global Cholangiocarcinoma Market are Agios Pharmaceuticals, AstraZeneca, Incyte Corporation, Eisai Pharmaceuticals, Decalth Systems, Basilea Pharmaceutica, Servier Pharmaceuticals, Taiho Oncology, TransThera Sciences and Roche.
Market Key Drivers:
Rising Cholangiocarcinoma cases to boost the growth of global Cholangiocarcinoma Market. For instance, as per NCI around 6 in 100,000 people suffer from Cholangiocarcinoma across the globe.
Increasing liver cancer along with rising awareness of therapeutics for cancer treatment is projected to propel the growth of global Cholangiocarcinoma Market. For instance, as per WCRF around 905,677 people were diagnosed with liver cancer across the globe.
Jul 18, 2019 (AB Digital via COMTEX) -- The Bile Duct Cancer Market Size To Project Lucrative CAGR of 9.2% By 2023 in the forecast period.
Intensifying number of bile duct cancer cases being diagnosed globally have fortified the need for cutting-edge solutions in terms of procedure and medicines to treat the condition.
Market reports associated with the healthcare sector made accessible by Market Research Future along with published reports on other sectors have been lately put out along with a report on this industry.
Bile Duct Cancer Market Segmental Analysis
The market for bile duct cancer is segmented based on
By diagnosis the bile duct cancer market is segmented into
Hypoparathyroidism Market DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hypoparathyroidism , historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hypoparathyroidism is an uncommon condition in which your body produces abnormally low levels of parathyroid hormone (PTH).
PTH is key to regulating and maintaining a balance of two minerals in your body — calcium and phosphorus.
Hypoparathyroidism Market PlayersShire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., EnteraBio LtdAnd Many Others Read More: https://www.delveinsight.com/report-store/hypoparathyroidism-market Lymphocytopenia Market DelveInsight's "Lymphocytopenia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Lymphocytopenia, historical and forecasted epidemiology as well as the Lymphocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lymphocytopenia is the condition of having an abnormally low level of lymphocytes in the blood.
It is also called lymphopenia.
